ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.74M | $622.00K | $240.00K | $934.00K | $605.00K | $43.00K | $47.00K | $45.00K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | $9.01M | $-3.11M | N/A |
| Gross Profit | $14.74M | $622.00K | $240.00K | $934.00K | $605.00K | $-8.97M | $3.16M | $45.00K |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | -20858.14% | 6717.02% | 100.00% |
| Operating Expenses | $358.93M | $362.87M | $351.54M | $331.21M | $221.49M | $57.94M | $101.55M | $99.17M |
| Operating Income | $-344.18M | $-362.25M | $-351.30M | $-330.28M | $-220.88M | $-66.91M | $-98.39M | $-99.12M |
| Operating Margin | -2334.23% | -58239.55% | -146374.17% | -35361.88% | -36509.09% | -155597.67% | -209338.30% | -220266.67% |
| Net Income | $-413.56M | $-583.20M | $-416.57M | $-346.79M | $-221.85M | $-65.79M | $-96.23M | $-96.42M |
| Net Margin | -2804.77% | -93761.41% | -173569.58% | -37129.55% | -36669.59% | -152997.67% | -204736.17% | -214273.33% |
| EPS (Basic) | $-0.59 | $-1.15 | $-1.04 | $-0.89 | $-0.59 | $-0.42 | $-0.30 | $-0.30 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |